At WCLC 2025, see efficacy and safety results from the LOXO-RAS-20001 and SUNRAY-01 trials, investigating 1L treatment with a KRAS G12C inhibitor + pembrolizumab in KRAS G12C-mutant non-small cell lung cancer (NSCLC).
👇 Click the link below to learn more.